Dominic Pilon, MA

  • 4Articles
  • 122.7KReads
  • 2018–2025Active
  • 20Collaborators
  • 627Citations

About

Dominic Pilon, MA, is affiliated with Analysis Group, Inc in Montréal, Quebec, Canada. Pilon has published extensively on major depressive disorder (MDD), treatment-resistant depression, and suicide, focusing on economic and productivity impacts in these populations. Contributions include analyses of work productivity loss, cost burden, and employment status changes related to depression treatments. Pilon's work has appeared in Psychiatrist.com between 2018 and 2025.

Publications

JCP
Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression
Original Research

Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression

January 27, 2025

Esketamine was associated with significantly larger improvements in work productivity loss and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.
, , , et al
JCP
Economic Burden of MDD and Suicidality
Original Research

Economic Burden of MDD and Suicidality

April 4, 2022

Acute suicidal ideation or behavior (SIB) that accompanies major depressive disorder (MDD) may produce a substantial economic burden. This study evaluated health care resource utilization and costs of commercially...
, , , et al
JCP
Original Research

Prevalence and Burden of TRD and MDD

March 16, 2021

How prevalent is treatment-resistant depression (TRD), and what proportion of the burden of medication-treated major depressive disorder is accounted for by TRD? This study explores those questions using the...
, , , et al
JCP
Original Research

Burden of Treatment-Resistant Depression

February 20, 2018

Read why treatment resistant depression, even compared to MDD, poses a significant direct and indirect cost burden to US employers and employment status.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe